A Phase I, Open-Label, Dose Escalation Study of ANG1005 in Patients with Advanced Solid Tumors and Metastatic Brain Cancer (ANG1005-CLN-02).
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2014
At a glance
- Drugs Paclitaxel trevatide (Primary)
- Indications Brain metastases; Solid tumours
- Focus Adverse reactions
- Sponsors AngioChem
- 15 May 2014 According to the Angiochem media release, the clinical data from this trial presented at the American Society of Clinical Oncology (ASCO) 50th Annual meeting May 30-June 3, 2014 in Chicago, IL.
- 09 Jun 2010 Changes: added actual pt number 56
- 09 Jun 2010 Status changed from active, no longer recruiting to completed.